No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 227 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent... March 5, 2026 Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... June 5, 2023 Load more HOT NEWS Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... Cancer in My Community: Overcoming Inequities in Care in Argentina Breast Cancer Warrior’s Emotional Photoshoot Features Her Husband Shaving Her Head Cancer in My Community: Working to Eliminate the Stigma of Cancer...
